Business Model & Revenue
Savara is a clinical-stage rare-respiratory biopharma with a single near-term commercial asset: molgramostim, a recombinant human GM-CSF delivered once daily by nebulizer. In autoimmune PAP, anti-GM-CSF autoantibodies impair alveolar macrophage function, letting surfactant accumulate and choking gas exchange; inhaled GM-CSF restores macrophage maturation at the site of disease with minimal systemic exposure. IMPALA-2, the 24-week Phase 3 with 48-week safety published in NEJM, met its primary endpoint — greater improvement in pulmonary gas transfer (DLco) versus placebo — with secondary reductions in surfactant burden and whole-lung lavage procedures. It is the only pharmacotherapy to reach FDA review for this disease; today's standard of care is mechanical whole-lung lavage under anesthesia.
If approved, the commercial model is textbook ultra-rare launch: a small specialized field team targeting the pulmonologists and referral centers that manage PAP, an exclusive specialty-pharmacy distribution partnership already contracted, orphan-drug pricing against a population measured in the tens of thousands at most, and seven years of U.S. orphan exclusivity. The company has spent 2026 building exactly that infrastructure — which is why G&A nearly doubled — ahead of any revenue.
The balance-sheet architecture is unusual and approval-contingent: $131 million of cash at September 30 funds roughly three quarters of burn, while $150 million of incremental capital — a $75 million RTW Investments royalty purchase and $75 million of Hercules term loans — is contractually gated on FDA approval by March 31, 2027. Shareholders' downside protection is thin; 269.3 million shares outstanding after years of issuance means any CRL-forced raise lands on an already extended cap table. The second asset, FLT201, an AAV-based gene therapy for Gaucher disease type 1, sits in Phase 1/2 and is not yet a valuation driver, but its data are the natural second catalyst in any approved-molgramostim world.
Financial Highlights
P&L Trend (calendar 2026, pre-revenue)
| Quarter | Net Loss | Net Loss/Share | Period Note |
|---|---|---|---|
| Q1 2026 | ($37.3M) | ($0.15) | BLA review ongoing |
| Q2 2026 | ($40.2M) | ($0.16) | Review extended in April |
| Q3 2026 | ($43.0M) | ($0.17) | Launch buildout began |
| TTM | ($152.7M) | ($0.61) | — |
Q3 operating expenses rose 44% year over year to $44 million: R&D $25 million (+21%), G&A $19 million (+93%) on commercial-team scaling and stock compensation. Nine-month stock-based compensation reached $26.3 million versus $9.1 million a year earlier.
Liquidity and Financing Structure
| Item | Amount |
|---|---|
| Cash + short-term investments (9/30/26) | $131.3M |
| Total debt (Hercules facility) | $31.6M |
| Operating cash burn, 9M 2026 | $105M |
| Implied runway at current burn | ≈3 quarters |
| RTW royalty purchase, on approval by 3/31/27 | $75M |
| Hercules term loans, on approval by 3/31/27 | $75M |
| Shares outstanding | 269.3M |
Hercules covenant thresholds have been extended to April 1, 2027 for minimum unrestricted cash and September 30, 2027 for trailing net product revenue — both effectively approval-contingent. Molgramostim filings are also validated under accelerated review pathways in the EU and UK.
Valuation Scenarios (12-month, PDUFA-weighted)
| Scenario | Probability | Implied Value | Anchor |
|---|---|---|---|
| Approval | 55% | ≈$8.50 | First-mover orphan launch, $150M contingent financing unlocks, EU/UK decisions pending, below street's $11.06 consensus |
| Complete response letter | 45% | ≈$2.50 | Dilution at depressed prices funds a response cycle into 2027-2028 |
| Blended target | — | $6.00 | Scenario math ≈$5.80 plus EU/UK optionality |
Guidance: None financial (pre-revenue). Operational gates: November 22 PDUFA; potential US launch prepared through a specialty field team and exclusive specialty-pharmacy partnership already built, with commercial staffing substantially complete as of Q3 — meaning approval converts to revenue within a quarter, not a year of hiring.
Competitive Landscape
Savara would enter a market with no approved pharmacotherapy — competition is the disease's current management pathway, not a rival drug.
- Whole-lung lavage (standard of care): Physically washing surfactant from the lungs under general anesthesia at specialty centers; effective but burdensome, repeatable, and the comparator molgramostim reduced the need for in IMPALA-2 secondary analyses. Any approved drug that delays or avoids lavage changes practice.
- Off-label GM-CSF (sargramostim/Leukine, Sanofi): Inhaled or subcutaneous GM-CSF has been used off-label for years on small open-label studies; an approved, nebulizer-delivered, NEJM-backed molgramostim formalizes what pulmonologists already do — but also proves a repurposed generic route exists if CRL delays stretch on.
- Rituximab and immunosuppression (off-label): B-cell depletion targets the autoantibody driver and is used at some centers; no registrational program exists in aPAP, leaving it a fringe competitor with its own toxicity profile.
- Large-cap rare-respiratory franchises (Vertex, Boehringer Ingelheim): Compete for the same specialist prescriber attention (pulmonary referral centers) rather than the same indication; their absence from aPAP is exactly why Savara's small field team can own a concentrated prescriber base without fighting a bigger commercial machine for airtime — an underappreciated advantage of launching into a disease nobody else wants.
- Savara's own FLT201 (Gaucher type 1): Not a competitor, but the pipeline placeholder that determines whether Savara is a one-asset special situation or a rare-disease platform post-approval.
Moats:
- The only Phase 3-positive, NEJM-published dataset for any aPAP pharmacotherapy — a data barrier measured in years for any follower
- Seven years of U.S. orphan-drug exclusivity and priority-review pedigree if approved, plus orphan designations in the EU
- Pre-built commercial infrastructure — specialty field team, exclusive specialty pharmacy, patient-identification pathways — that a late entrant into an ultra-rare market would take 18-24 months to replicate
- Approval-contingent financing ($150 million from RTW and Hercules) that funds launch without an immediate post-approval raise
Catalysts
-
PDUFA action date — November 22, 2026: The binary. Approval converts a pre-revenue story into a financed first-mover orphan launch; a CRL resets the timeline into a 2027-2028 response cycle and forces a cash raise
-
EU and UK regulatory decisions: Molgramostim filings are validated under accelerated 150-day review pathways in both jurisdictions; ex-US approvals would add launch geography and licensing leverage within the 12-month window
-
US launch metrics — H1 2027 if approved: Orphan pricing disclosure, patient starts through the specialty pharmacy partnership, and time-to-lavage-reduction anecdotes are how the market will size peak sales in real time
-
Contingent financing execution: Draw of the $75 million RTW royalty purchase and up to $75 million Hercules term loans on approval by March 31, 2027 — the balance-sheet event that removes the overhang skeptics anchor on
-
FLT201 Phase 1/2 updates (Gaucher disease type 1): The AAV gene therapy program's durable-response data would give the equity a second valuation leg precisely when molgramostim de-risks or breaks it — and in an approved scenario, Savara becomes one of the few sub-$2 billion rare-disease companies with both a launching commercial asset and a clinical-stage gene therapy platform in the house
Key Risks
- Regulatory — the FDA's April extension was triggered by a major amendment to the BLA; the agency's questions were never fully disclosed, and history says extension-triggering amendments carry materially elevated CRL risk even with NEJM-grade data
- Financing — $131.3 million of cash against $44 million of quarterly operating spend is ≈3 quarters of runway; a CRL forces dilution at depressed prices, and even approval consumes the $150 million contingent facility quickly at launch-burn rates
- Commercial — aPAP is ultra-rare with contested diagnosis rates; orphan pricing and reimbursement for an inhaled biologic are untested, and whole-lung lavage is entrenched and reimbursed practice at the referral centers Savara must convert
- Single-asset concentration — molgramostim is effectively the entire valuation; FLT201 is years behind and cannot cushion a regulatory failure
- Share-count overhang — 269.3 million shares outstanding after repeated issuance, with stock-based compensation tripling year over year to $26.3 million for nine months; any post-CRL or launch-funding raise lands on an extended cap table
Our Thesis
Autoimmune PAP is the rare-disease setup investors say they want and rarely get: a mechanistically understood disease (anti-GM-CSF autoantibodies blocking surfactant clearance in the alveoli), a validated endpoint (DLco gas transfer), a 90%-of-cases addressable subtype, an entrenched but barbaric standard of care in whole-lung lavage, and a Phase 3 published in NEJM showing once-daily inhaled molgramostim improved gas transfer versus placebo with clean 48-week safety. Priority review was granted; the April extension came from a major amendment to the application — the market read that as regulatory friction and sold the stock from its $7.00 52-week high to $4.48, a level that now embeds substantial CRL probability against consensus price targets of $11.06 from nine covering analysts.
Our $6.00 target is a scenario blend, not a multiple: 55% approval, where a de-risked, financed, first-mover orphan launch with EU and UK filings validated under accelerated pathways supports ≈$8.50; 45% CRL, where $131 million of cash against a rising $40 million-plus quarterly burn forces dilution near ≈$2.50. The approval case is helped by what the extension was not — a deficiency letter — and by regulatory validation in Europe; the CRL case rests on the FDA's history with extension-triggering amendments. At $4.73 the expected value is ≈24% upside against binary downside. That is a Speculative Buy, explicitly sized as such.
Get reports like this delivered free
New small-cap research every week. No paywall, no fluff.